Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction
Fasiha Kanwal, Amit G. Singal
Gastroenterology (2019) Vol. 157, Iss. 1, pp. 54-64
Open Access | Times Cited: 396

Showing 26-50 of 396 citing articles:

Kinesin family members KIF2C/4A/10/11/14/18B/20A/23 predict poor prognosis and promote cell proliferation in hepatocellular carcinoma.
Xishan Li, Weimei Huang, Wenbin Huang, et al.
PubMed (2020) Vol. 12, Iss. 5, pp. 1614-1639
Closed Access | Times Cited: 59
ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma
Yuta Myojin, Takahiro Kodama, Kazuki Maesaka, et al.
Clinical Cancer Research (2020) Vol. 27, Iss. 4, pp. 1150-1161
Open Access | Times Cited: 59
Exosomal microRNA‐4661‐5p–based serum panel as a potential diagnostic biomarker for early‐stage hepatocellular carcinoma
Hyo Jung Cho, Geum Ok Baek, Chul Won Seo, et al.
Cancer Medicine (2020) Vol. 9, Iss. 15, pp. 5459-5472
Open Access | Times Cited: 54
Diagnostic and Therapeutic Delays in Patients With Hepatocellular Carcinoma
Ashwin Rao, Nicole E. Rich, Jorge A. Marrero, et al.
Journal of the National Comprehensive Cancer Network (2021) Vol. 19, Iss. 9, pp. 1063-1071
Open Access | Times Cited: 54
Elevated FBXO45 promotes liver tumorigenesis through enhancing IGF2BP1 ubiquitination and subsequent PLK1 upregulation
Xiaotong Lin, Hongqiang Yu, Lei Fang, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 54
Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters
Sean Woolen, Amit G. Singal, Matthew S. Davenport, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 1, pp. 204-215.e6
Open Access | Times Cited: 50
Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality
Hyun‐Seok Kim, Xiangjun Xiao, Jinyoung Byun, et al.
JAMA Network Open (2022) Vol. 5, Iss. 10, pp. e2234221-e2234221
Open Access | Times Cited: 38
Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View
Maen Abdelrahim, Abdullah Esmail, Ashish Saharia, et al.
Cancers (2022) Vol. 14, Iss. 7, pp. 1760-1760
Open Access | Times Cited: 36
Polyphenols as potential metabolism mechanisms regulators in liver protection and liver cancer prevention
Shuangfeng Li, Shuangshuang Yin, Hui Ding, et al.
Cell Proliferation (2022) Vol. 56, Iss. 1
Open Access | Times Cited: 36
Exhaled volatile organic compounds for diagnosis of hepatocellular carcinoma
Thanikan Sukaram, Rossarin Tansawat, Terapap Apiparakoon, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 32
Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma
Xingyu Peng, Jinfeng Zhu, Sicheng Liu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 32
Enhanced glypican-3-targeted identification of hepatocellular carcinoma with liver fibrosis by pre-degrading excess fibrotic collagen
Jiaming Zhuo, Yueqi Wang, Hui Hui, et al.
Acta Biomaterialia (2023) Vol. 158, pp. 435-448
Closed Access | Times Cited: 22
Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma
Yang Song, Harry Cheuk-Hay Lau, Xiang Zhang, et al.
Cancer Biology and Medicine (2023), pp. 1-19
Open Access | Times Cited: 17
Review of Related Factors for Persistent Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma
Nevin Varghese, Amry Majeed, Suraj Nyalakonda, et al.
Cancers (2024) Vol. 16, Iss. 4, pp. 777-777
Open Access | Times Cited: 8
Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study
De‐Zhen Guo, Ao Huang, Ying‐Chao Wang, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 5
Open Access | Times Cited: 8
High Ki67 Gene Expression Is Associated With Aggressive Phenotype in Hepatocellular Carcinoma
Vicente Ramos‐Santillan, Masanori Oshi, Erek Nelson, et al.
World Journal of Oncology (2024) Vol. 15, Iss. 2, pp. 257-267
Open Access | Times Cited: 7
IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating β-catenin
Yarong Guo, Jun Xu, Qiang Du, et al.
Translational Oncology (2021) Vol. 14, Iss. 6, pp. 101059-101059
Open Access | Times Cited: 36
We need stronger evidence for (or against) hepatocellular carcinoma surveillance
Peter Jepsen, Joe West
Journal of Hepatology (2021) Vol. 74, Iss. 5, pp. 1234-1239
Open Access | Times Cited: 35
Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis
Rajalakshmi Govalan, Marie Lauzon, Michael Luu, et al.
Liver Cancer (2021) Vol. 10, Iss. 5, pp. 407-418
Open Access | Times Cited: 33
Urine DNA biomarkers for hepatocellular carcinoma screening
Amy K. Kim, James P. Hamilton, Selena Y. Lin, et al.
British Journal of Cancer (2022) Vol. 126, Iss. 10, pp. 1432-1438
Open Access | Times Cited: 28
Resistance of Lenvatinib in Hepatocellular Carcinoma
Qiuran Xu, Dong‐Sheng Huang, Jinhui Guo, et al.
Current Cancer Drug Targets (2022) Vol. 22, Iss. 11, pp. 865-878
Closed Access | Times Cited: 27
The latest research progress on minimally invasive treatments for hepatocellular carcinoma
Yawen Zou, Zhigang Ren, Ying Sun, et al.
Hepatobiliary & pancreatic diseases international (2022) Vol. 22, Iss. 1, pp. 54-63
Closed Access | Times Cited: 26
CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis
Anli Jin, Chunyan Zhang, Wenjing Zheng, et al.
Clinical and Translational Medicine (2022) Vol. 12, Iss. 4
Open Access | Times Cited: 25
Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis
Jaideep Behari, Amir Gougol, Renwei Wang, et al.
Hepatology Communications (2023) Vol. 7, Iss. 7
Open Access | Times Cited: 16
A Liver Stiffness–Based Etiology-Independent Machine Learning Algorithm to Predict Hepatocellular Carcinoma
Huapeng Lin, Guanlin Li, Adèle Delamarre, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 3, pp. 602-610.e7
Closed Access | Times Cited: 16

Scroll to top